Peripheral T cell lymphomas are a heterogeneous group of post-thymic, mature lymphoid malignancies, accounting for approximately 10-15% of all non-Hodgkin's lymphomas. A rare entity within this group is represented by hepatosplenic ␥␦ T cell lymphoma, which is characterized by primary extranodal disease with typical sinusoidal or sinusal infiltration of the liver and the spleen, respectively, by expression of the T cell receptor ␥␦ chain, and by a number of other frequent clinicopathological features including aggressive course of disease. In contrast to these common attributes some biologic characteristics such as expression of cytotoxic proteins and cytotoxic activity have been controversial. In this review, clinicopathological, immunophenotypical, molecular biological, cytogenetical and biological findings, and diagnostic and therapeutic difficulties in hepatosplenic ␥␦ T cell lymphoma are discussed. Leukemia (2000) 14, 991-997.
Introduction
In 1990, hepatosplenic ␥␦ T cell lymphoma was recognized as a distinct lymphoma entity by Farcet et al 1 who analyzed in detail two previously described peripheral ␥␦ T cell lymphomas 2 with predominant infiltration of the spleen and the liver. Since then, to our knowledge 44 cases have been described. Because of similar clinicopathological appearance, some additional cases have been discussed to represent hepatosplenic ␥␦ T cell lymphomas, however, in these cases ␥␦ T cell receptor studies were not available. [30] [31] [32] [33] [34] [35] [36] A few more cases have been documented in studies on particular issues and are not available in detail. [37] [38] [39] Typical features are sinusoidal infiltration of the liver and sinusal infiltration of the spleen, no lymphadenopathy, an aggressive clinical course, and a predominance of young male adults. 15, 29 Despite use of a variety of treatment regimens including bone marrow or peripheral stem cell transplantation it has not been possible to establish an effective treatment. 29 Because of the abovementioned clinicopathological features and the frequent presence of an isochromosome 7q often associated with trisomy 8, hepatosplenic ␥␦ T cell lymphoma was recognized as a distinct lymphoma entity by the REAL classification in 1994. 40 The present article intends to discuss clinical and biological features of the published cases, and an additional case in our institution.
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Patients
Of the 45 cases reviewed, 41 were evaluable for age and sex. Two of the patients were under the age of 16 and three had exceeded the age of 50 years. The median age was 29 years (range 5-68 years) ( Table 1) . Thirty-four of the patients were male and seven female (Table 1) . Nine patients developed the neoplasm following kidney transplantation (n = 6), heart transplantation (n = 1), Hodgkin's disease (n = 1) and AML (n = 1) ( Table 1) .
Presentation and diagnosis
The majority of the patients presents with hepatosplenomegaly and systemic symptoms 41 (Table 2) . Other clinical features such as fatigue, jaundice due to hepatic involvement and Coombs negative hemolytic anemia, and purpura may occur. Lymphadenopathy has been reported only in a few patients at presentation of the disease. 10, 18, 23 The predominant laboratory findings are reduced peripheral blood cells ranging from isolated reduction of one lineage to pancytopenia, elevated lactate dehydrogenase, and pathologic liver parameters ( Table 2 ). The finding of pancytopenia and normal bone marrow has generated the hypothesis that cytokines produced by the malignant ␥␦ T cells may suppress bone marrow precursor cells, 8, 17 however, data providing strong evidence for this hypothesis are missing.
Diagnosis of the disease has been complicated in some cases by misleading symptoms. For example, isolated thrombocytopenia which disappeared after splenectomy has been misinterpreted as idiopathic thrombocytopenic purpura, 15, 16 circulating blast-like lymphoma cells were erroneously interpreted as acute lymphoblastic leukemia blasts, 18 or presentation with hepatosplenomegaly, jaundice, elevated liver parameters, thrombocytopenia, and fever have led to the assumption of a virus infection, which has usually not been confirmed. 5, 21, 26, 29 Even more difficulties regarding the diagnosis of hepatosplenic ␥␦ T cell lymphoma may result from not considering this rare entity as a differential diagnosis. In most of the cases splenectomy or liver biopsy should be sufficient to establish diagnosis. Furthermore, splenectomy has been reported to improve the patients' condition for variable time (Refs 1, 4, 16, 21 and Table 1 ).
Histopathology
The most common feature present in almost all patients with hepatosplenic ␥␦ T cell lymphoma is infiltration by malignant cells of the spleen and frequently of the liver (Table 2) . Bone marrow involvement is seen in approximately two-thirds of the patients at diagnosis, more often in progressive course of disease, lymphadenopathy is rare 10, 18 and sometimes associated with infiltration of other organs by malignant cells in the terminal stage of disease. 5, 6 In the spleen, the red pulp is generally diffusely invaded and expanded by malignant ␥␦ T cells 3, 15 resulting in an increased mass, whereas the white pulp can appear from normal to reduced to small residual areas. Normal ␥␦ T cells have been shown to be also localized in the splenic sinuses, probably due to special homing receptors. 42 Therefore, and because of the sometimes sole involvement of the spleen it seems likely that hepatosplenic ␥␦ T cell lymphoma originates in the splenic red pulp. 15 A known phenomenon in peripheral T cell lymphomas and also documented in areas invaded by malignant hepatosplenic ␥␦ T cells is erythrophagocytosis. [1] [2] [3] 8, 18, 22, 23, 26 Besides peripheral cytopenia, this feature may be another indicator for active cytokine production by the tumor. 18 Tumor necrosis factor ␣ has been presumed to be responsible for histiocyte activation and subsequent erythrophagocytosis in EBV transformed T cell lymphomas. 43 However, hepatosplenic ␥␦ T cell lymphoma is generally not EBV associated. In the liver, the typical site of infiltration is the sinusoids, but marked or even exclusive portal infiltration has been reported in some cases ( Figure 1) . 1, 2, 5, 28 Bone marrow, if affected, is usually hypercellular with a sinusoidal distribution of the T cells. [15] [16] [17] [18] 20 Malignant hepatosplenic ␥␦ T cells are usually of small to medium size with relatively regular or folded nuclei, mostly inconspicuous nucleoli, and with a mature dispersed chromatin and a pale blue, not granulated, somewhat abundant cytoplasm. Blast-like appearance at diagnosis is rare, 18 however, terminal transformation to blast-like cells with large nucleoli has been reported several times (Refs 6, 9, 11, 20 and case 45).
Immunophenotype
A phenotype which has been accepted to be common in hepatosplenic ␥␦ T cell lymphoma is CD2
. TCR-V␦ expression seems to be restricted to V␦1. NK-related antigens CD16 and CD56 are frequently expressed (Table 3) . As may be expected, there are many exceptions to this 'common phenotype' since expression of CD5, CD7, CD8, CD16 and CD56 is variable (Table 3) . Even expression of CD3 and TCR-␥␦ has been lost in one case at presentation of relapse, 1 and CD7 in another patient after chemotherapy. 15 Additionally, weak to strong expression of CD8 as in some populations of normal ␥␦ T cells, 42 which are usually CD4 and CD8 negative, has been described. Absence of common T cell antigens as CD5 or CD7 has been associated with peripheral T cell lymphomas. 15 CD7, a molecule which acts as an activator of various NK Leukemia and T cell populations including normal ␥␦ T cells 44, 45 was expressed in two-thirds of the cases (Table 3 ). Other molecules associated with activation but not strictly restricted to T cells such as CD11b, CD11c, CD38, CD43, and Fas ligand are frequently expressed (Table 3 ). B cell markers (CD19, CD20, CD21, CD22), immunoglobulins, TCR-␣␤ chain, TdT, CD10, CD15, CD25, CD33, CD34, CD41, and CD68 were consistently negative (data not shown). Ki67 was studied in one patient: at diagnoses it was not detectable, but in blast transformation it turned out to be strongly positive 8 (data not shown).
Regarding expression of cytotoxic granule-associated proteins, the data are somewhat conflicting. A study by Boulland and coworkers 37 Table 3 ). The latter may be supported by the demonstration of cytotoxicity by malignant ␥␦ T cells in three cases as described below.
Molecular rearrangement studies
In the initial report of hepatosplenic ␥␦ T cell lymphoma Southern analysis of the T cell receptor (TCR) ␤ and ␦ chain genes demonstrated clonality of the cells.
1 V␦1 associated with different V␥ regions has been identified to be the predominant V␦ region (Refs 7, 15, 22, 24, 28 and Table 3 ). Nonproductive TCR ␤-chain rearrangements have been confirmed frequently (Refs 6, 7, 10, 22, 24, 28 and Table 3 ).
Garcia-Sanchez et al 11, 12 utilized TCR rearrangements for monitoring of disease follow-up. They sequenced a TCR-␦ VDJ product and designed a clone-specific probe by which they were able to detect the malignant clone in spleen, bone marrow, peripheral blood and liver. After treatment, only a liver specimen was still positive. 11 Weirich and coworkers 25 amplified DNA from fixed decalcified bone marrow and demonstrated invasion of the spleen by the identical ␥␦ T cell clone, although the splenic population appeared as a 'highgrade' lymphoma and the ␥␦ T cells in the bone marrow as 'low-grade' lymphoma cells. These data suggested a common precursor cell for both forms of the lymphoma cells. Histology and immunohistochemistry of a fine needle liver biopsy performed after the first cycle of chemotherapy in case 45 (see Table 1 ). Following chemotherapy peripheral ␥␦ T cells were markedly reduced and hepatosplenomegaly decreased. (a) Hematoxylin and eosin staining; (b) staining with anti-CD3; and (c) staining with anti-CD20 antibodies (all ×200). In this case, as in a few others, main infiltration of the liver by the lymphoma cells was noted in the portal areas. Sinusoidal infiltration was present but negligible.
Cytogenetics
In 19 of the reviewed cases, karyotypes of ␥␦-lymphoma cells were available (Table 4) . Earlier studies showed the presence of an isochromosome 7q, often associated with trisomy 8, 9, [13] [14] [15] inspiring the discussion that isochromosome 7q may represent the primary chromosomal aberration accompanied by trisomy 8 as a secondary change. 9 Meanwhile isochromosome 7q has been detected in 13 of the patients, all of them male, and associated with trisomy 8 in 10 cases, however, trisomy 8 without isochromosome 7 has not been reported (Table 4) . Although isochromosome 7q and trisomy 8 by themselves are known cytogenetic abnormalities in a number of hematological malignancies and solid tumors 47 the combination of both seems to be unique in hepatosplenic ␥␦ T cell lymphoma. On the other hand in some patients with clear clinicopathological criteria of hepatosplenic ␥␦ T cell lymphoma different karyotypes of the malignant cells were shown ( Table 4 ), suggesting that although the combination of isochromosome 7q and trisomy 8 has been proposed to classify hepatosplenic ␥␦ T cell lymphoma as a distinct entity 41 the karyotype alone is not sufficient to define the disease. Earlier studies suggested isochromosome 7q to be an adverse prognostic factor. 18 The present evaluation of karyotypes does not support this hypothesis. The median survival in patients with isochromosome 7q was 7.5 months as compared to 10 months in the total population and 5 months in patients with other aberrations. Consequently, the prognostic value of chromosomal aberrations in hepatosplenic ␥␦ T cell lymphoma remains undetermined.
Cytotoxicity
Functional data of malignant ␥␦ T cells have been obtained in three cases with hepatosplenic ␥␦ T cell lymphoma. Falcao and coworkers 4 were the first to demonstrate NK activity of ␥␦ T cells in their case by lysis of K562 cells. Salhany et al 18 studied cytotoxic activity of ␥␦ T cells against the P815 cell line in two of their patients. Spontaneous cytotoxicity was not observed, however, after incubation with anti-CD3 or anti-CD16 the ␥␦ T cells from one patient were able to mediate some lytic activity. 18 In our case (case 45) the lymphoma cells exhibited strong cytotoxicity against K562 cells and moderate lysis of Daudi cells. Altogether the data indicate that at least some hepatosplenic ␥␦ T cell lymphomas consist of mature cytotoxic ␥␦ T cells. Specific T cell receptor-mediated cytotoxic activity by the tumor cells seems unlikely. 48 
Treatment and outcome
Of the patients available for treatment and response, four were alive at the time when the reports were finished, one in CR after m-BACOP, two in CR after allogeneic bone marrow transplantation, and one patient alive with a 6 year history of untreated hepatosplenic ␥␦ T cell lymphoma followed by CHOP because of disease progression (Table 1) . One patient died in CR from sepsis due to aplastic anemia without evidence of disease (case 28, Table 1 ). 36 patients were dead from disease at the time when their cases were reported. Of these, the median survival was 8 months (range 0-42 months, Table 1 ). Treatment included splenectomy, steroids, alkylating agents, CHOP or CHOP-like therapies, second or third generation regimens for high-grade lymphomas, purine analogues, multiagent therapy approaches, and autologous and allogeneic bone marrow or peripheral stem cell transplantation (Table 1) . Complete remissions were reported only in five of these 36 patients (cases 1-3, 34, and 45; Table 1 ). Considering that the observation time after allogeneic transplantation was short, that -although many approaches have been attempted -induction of CR has been rare, and that relapses are common and occur early, one has to conclude that cura-995 Table 3 Immunophenotype, and rearrangements of T cell receptor and immunoglobulin genes in hepatosplenic ␥␦ T cell lymphoma CD1  CD2  CD3  CD4  CD5  CD7  CD8  CD30  CD38  CD43  TCR-V␦1  TCR-V␦2  TCR- In total, 45 patients were reviewed. Shown are positive antigens or rearrangements in relation to the numbers of patients studied for the respective marker. The case numbers correspond to those in Table 1 .
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tive treatment is not available in hepatosplenic ␥␦ T cell lymphoma. Initial improvement has been observed in the majority of cases, no matter whether splenectomy, oral treatment with steroids or alkylating agents, or aggressive approaches have been attempted. Thus, the question of whether aggressive treatment improves the overall survival is unresolved. Possibly transplantation after a short attempt to induce remission might be a suggestion, however, the data do not provide enough evidence to give general recommendations.
Concluding remarks
Because of a variety of common features hepatosplenic T cell lymphoma is generally considered a distinct lymphoma entity. It can be distinguished from most other lymphoma types by Leukemia the combination of TCR-␥␦ gene rearrangement and expression, primary involvement of the spleen and the liver with a typical sinusal or sinusoidal infiltration pattern, respectively, extranodal disease, and some other rather common features as presentation with hepatosplenomegaly and peripheral cytopenia, a typical immunophenotype, and the frequent presence of isochromosome 7q and trisomy 8. Differential diagnoses include T-lymphoblastic lymphomas expressing TCR ␥␦, 49 peripheral cytotoxic T cell lymphomas, [50] [51] [52] and unusual forms of T-chronic lymphocytic/promyelocytic leukemias with CD8 phenotype. 53, 54 TCR ␥␦ T-lymphoblastic lymphomas may be excluded by expression of TdT. 41, 49 Clinicopathological and immunological overlaps with cytotoxic T cell lymphomas, unusual CD8 + T-CLL/PLL and so called 'S100-positive T-chronic lymphoproliferative disease (T-CLPD)' are possible, because hepatosplenomegaly, an aggressive clinical course, lack of azurophilic granules, and expression of CD8 are common. Especially in S100 T-CLPD hepatosplenic infiltration is sinusoidal or sinusal, respectively. However, all of these entities usually express the TCR-␣␤ chains. [50] [51] [52] [53] [54] In cases which can not be clarified by clinicopathology, immunology, and standard molecular biology more sophisticated molecular approaches as indicated above should be involved. As the disease is rare its biology is not yet well understood. However, because of the dilemma of an aggressive clinical course and an unsatisfactory response to treatment, more insight in the biology of the malignant ␥␦ T cells may hopefully contribute to develop new therapeutic concepts.
